ETANA STRENGTHENS NATIONAL PHARMACEUTICAL INDEPENDENCE THROUGH CLINICAL RESEARCH ON DIABETES THERAPHY WITH RSUI

Jakarta, July 14, 2025 – PT Etana Biotechnologies Indonesia (Etana), a national biopharmaceutical company focused on developing treatments for metabolic and chronic diseases, has signed a collaboration agreement with Universitas Indonesia Hospital (RSUI) to conduct clinical research on therapy for Type 2 Diabetes Mellitus.

This initiative reflects Etana’s commitment to delivering biotechnology-based innovations that have a tangible impact on public health while also supporting the independence of the national pharmaceutical industry. The therapy under investigation is based on advanced technology and is designed to address the challenges of managing chronic diseases, whose prevalence continues to rise in Indonesia.

“We believe that clinical research on GLP-1 products for the treatment of diabetes and obesity is a breakthrough that can make a significant contribution—not only clinically but also in supporting the independence of the national pharmaceutical industry. Our goal is to help make this therapy accessible to all segments of the Indonesian population,” said Liauw Tek Kim, Chief Financial Officer of Etana.

He further explained that the drug being developed in this research is locally produced at Etana’s manufacturing facility in Indonesia and carried out entirely by domestic experts. To date, available therapies in the market have been largely dominated by imported products. From an effective and efficiency standpoint, Etana ens ures its product quality is on par with imported alternatives, while offering a key advantage significantly more affordable pricing.

The research is conducted in collaboration with RSUI as a strategic partner from the academic and healthcare sectors. The clinical trial will be carried out rigorously and scientifically, involving Prof. Dr. dr. Pradana Soewondo, Sp.PD-KEMD—a leading endocrinologist and academic from Universitas Indonesia—as the principal investigator. All processes will strictly follow scientific principles, clinical trial protocols, and applicable medical ethics to ensure the therapy’s safety and efficacy before it becomes widely available to the public.

RSUI President Director, Dr. Kusuma Januarto, Sp.OG, Subsp. Obginsos, emphasized that the hospital’s involvement in this clinical trial reflects its role as a teaching hospital that actively supports the advancement of medical science and technology.

“Through clinical research that prioritizes patient safety and benefit, RSUI will contribute to the innovation of diabetes therapies that provide meaningful impact to society, particularly for patients with chronic diseases such as diabetes,” he said.

As a teaching hospital ranked among the Global Top 250 Hospitals by Brand Finance, RSUI continues to strengthen its strategic research collaborations at both national and international levels. The joint research with Etana is a concrete example of synergy between industry, academia, and healthcare services.

This collaboration is expected to lay the foundation for developing innovative therapies that meet the specific needs of the Indonesian population, while reinforcing national health development rooted in research and scientific knowledge.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.